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Abstract
Rapid antigenic evolution in the influenza A virus hemagglutinin precludes effective vaccination
with existing vaccines. To understand this phenomenon, we passaged virus in mice immunized with
influenza. Neutralizing antibodies selected mutants with single amino acid hemagglutinin
substitutions that increased virus binding to cell surface glycan receptors. Passaging these high
avidity-binding mutants in naïve mice, but not immune mice, selected for additional hemagglutinin
substitutions that decreased cellular receptor binding avidity. Analyzing a panel of monoclonal
antibody hemagglutinin escape mutants revealed a positive correlation between receptor binding
avidity and escape from polyclonal antibodies. We propose that in response to variation in
neutralizing antibody pressure between individuals, influenza A virus evolves by adjusting receptor
binding avidity via amino acid substitutions throughout the hemagglutinin globular domain, many
of which simultaneously alter antigenicity.
Influenza A virus remains an important human pathogen due largely to its ability to evade
antibodies specific for its attachment protein, the hemagglutinin (HA). This “antigenic drift”
is due to accumulation of amino acid substitutions in HA epitopes recognized by antibodies
that neutralize viral infectivity by blocking interaction of HA with sialic acid residues on host-
cell membranes (1–3). The H1 subtype HA has four antigenic sites recognized by monoclonal
antibodies with high neutralizing activity, designated Sa, Sb, Ca, and Cb (4). How can HA
escape polyclonal antibodies given that the frequency of variants with simultaneous multiple
point mutations is exceedingly low (5)? A popular model posits sequential selection by
different individuals whose antibody responses focus on different individual antigenic sites
(6,7).
To better understand how antigenic drift occurs in human populations, we revisited classical
experiments modeling drift in outbred Swiss mice (8). We generated three separate infectious
stocks of the mouse-adapted strain A/Puerto Rico/8/34 (H1N1) (PR8) in MDCK cells using
*To whom correspondence should be addressed; jyewdell@mail.nih.gov.
Supporting Online Material
www.science.org
Methods
Figs. S1 to S7
Tables S1 to S3
NIH Public Access
Author Manuscript
Science. Author manuscript; available in PMC 2010 October 30.
Published in final edited form as:
Science. 2009 October 30; 326(5953): 734–736. doi:10.1126/science.1178258.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
reverse genetics. Each stock was serially passaged in naïve mice or mice immunized with
inactivated virus. Mice were infected intranasally with virus prepared from lung homogenates.
After nine passages, HA gene sequencing revealed no detectable mutations in viruses passaged
in naïve mice (Fig. 1A). By contrast, each lineage from vaccinated mice contained a
predominant population with a different single amino acid substitution: residue 158 (E to K,
lineage I), 246 (E to G, lineage II), or 156 (E to K, lineage III). Residue 158 is located at the
interface of the Sa/Sb antigenic sites, residue 156 is in the Sb site, and residue 246 is located
outside the defined epitopes (4) (Fig. 1B). E158K, initially detected in lineage I following
passage 2, predominated by passage 3 (Table S1). In lineage II, E246G abruptly emerged during
passage 3. In lineage III, E158K and E156K co-dominated from passage 2–7, with E156K
predominating following passage 8. None of the lineages exhibited changes in the
neuraminidase gene.
We measured the mutants’ ability to escape antibody responses by hemagglutination inhibition
(HAI) and virus neutralization assays using immune serum pooled from 45 PR8-vaccinated
mice. Each mutant escaped antibody responses in these ternary (virus, antibody & cell) assays
(Fig. 1C–D), despite demonstrating only minor (E156K, E158K) or no (E246G) decreases in
anti-HA antibody binding (Fig. 1E). More precise antigenic analysis using ELISA confirmed
that the amino acid substitutions had limited effects on individual monoclonal antibody binding
(Fig. S1). E156K modified Sb antigenicity, but had no effect on the other sites. E158K altered
binding of a subset of Sa- and Sb- specific monoclonal antibodies. Notably, just one of 16
monoclonal antibodies tested exhibited (slightly) altered binding to E246G, consistent with
the observation that the substitution resides outside defined antigenic sites (4).
HA mutations can decrease HAI antibody activities by increasing the viral HA binding avidity
for cell surface glycan receptors (9,10)(11). Relative to wt virus, such “adsorptive mutants”
exhibit enhanced agglutination of erythrocytes treated with V. cholerae neuraminidase receptor
destroying enzyme (RDE) to remove terminal sialic acids, the cellular HA ligand. Strikingly,
relative to wt virus, each mutant better agglutinated RDE-treated erythrocytes (Fig. 1F).
Mutant-virus hemagglutination was also more resistant to competition from horse serum “non-
specific” inhibitors (Fig. S2), confirming increased cellular receptor binding avidity. Mutant
viruses also exhibited higher binding avidity than wt virus to both α2–3 and α2–6 sialylated
glycans in a dose-dependent, direct glycan receptor-binding assay (Fig. S3).
E156K and E158K mutants were again selected when different PR8 stocks (propagated in
either eggs or MDCK cells) were passaged in PR8-immunized BALB/c or C57BL/6 mice,
indicating that these are particularly adept escape mutants. As these substitutions modify
antigenicity (unlike E246G and previously described adsorptive mutants (10)), this suggests
that polyclonal antibody escape favors substitutions that simultaneously increase cellular
receptor binding and diminish antigenicity.
These findings prompted us to examine the cellular receptor binding avidities of forty
monoclonal antibody selected HA-escape mutants (4). Each amino acid substitution in the
panel exerts similar relatively minor effects on HA antigenicity (4). Surprisingly, twenty three
mutants exhibited altered binding to RDE treated-erythrocytes (Fig. 2A,Table S2). There was
a strong correlation between cellular receptor binding and polyclonal antibody HAI escape
(Fig. 2B). Substitutions modifying receptor binding cover all four antigenic sites (Fig. 2A,C).
Of eighteen substitutions that enhance receptor binding, eleven increased HA positive charge
(Fig. 2D) (Table S2). Since virions possess ~ 900 HA monomers (12), increased positive charge
may enhance cellular receptor binding by increasing charge attraction with negatively charged
cell surfaces (13). Retrospective analysis supports a relationship between H3 HA charge and
receptor binding (14).
Hensley et al. Page 2
Science. Author manuscript; available in PMC 2010 October 30.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Upon further passaging in vivo selected virus populations in mice vaccinated with homologous
inactivated virus (e.g., E156K virus passaged in E156K-vaccinated mice), we detected minor
virus populations with novel amino acid substitutions distant from the sialic acid binding site,
often distant from defined neutralizing epitopes (Table S3, Fig. S4). Substitutions that
enhanced receptor binding (Fig. 3A) enhanced polyclonal HAI antibody escape (Fig. 3B).
Optimizing viral fitness requires balancing host cell receptor binding of input virus with release
of progeny virus. Strikingly, passaging in vivo selected mutants in naïve mice selected mutants
(Table S3) with reduced cellular receptor binding avidity (Fig. 3A). Mutations selected by
naïve mouse passage decreased polyclonal HAI antibody escape (Fig. 3B). E158K- and
E246G-derived mutants were inhibited at similar levels as wt PR8, demonstrating the central
role of cellular receptor binding in E158K and E246G single point mutants escape from
polyclonal antibodies (see also Fig. 1E). E156K viruses with secondary mutations acquired in
naïve mice still escaped wt-specific polyclonal antibodies better than wt virus, despite a return
to wt binding avidity, demonstrating that E156K alteration of Sb antigenicity contributes to
immune escape.
Despite the absence of antibody selection, some secondary mutations selected in naïve mice
modified HA antigenicity (Fig. S1). A227T, located near the sialic acid-binding site, reduced
binding of the Sa-specific antibody, IC5-2A7. R220G reduced binding of the Sa-specific
antibody, H2-6A1. Thus, antigenic drift can be a by-product of Darwinian selection for
mutations that optimize host cell receptor binding during influenza virus transmission between
immune (increased receptor binding) and naïve individuals (decreased receptor binding).
To demonstrate an independent role for cellular receptor binding avidity in polyclonal antibody
mediated evolution, we co-infected mice with wt PR8 and AM6, an absorptive mutant with a
substitution (P186S) in the receptor binding site that does not modify antigenicity (10,15) (Fig.
S5A). AM6 was rapidly selected in vaccinated but not naïve mice (Fig. S5B). Next, we
coinfected mice with E246G virus (minor antigenic change/high receptor binding) and E246G/
A227T (greater antigenic change/low receptor binding). Vaccinated mice selected E246G
while naïve mice selected E246G/A227T (Fig. S5D), confirming the critical role of binding
avidity in antibody-driven viral evolution.
To extend our drift model, we passaged E156K/R220G in mice given a high vaccine dose to
generate severe antibody selection pressure. This resulted in the evolution of E156K/R220G/
I244T (no selection occurred in naïve mice). I244T, located in the Sa/Ca interface (Fig. S6A),
increased cellular receptor binding (Fig. 3C), and as predicted, increased polyclonal HAI
antibody escape to levels exhibited by the E156K progenitor (Fig. 3D). Thus, during these
passages between naïve and immune individuals, influenza A virus exhibited three cellular
receptor binding avidity changes that were completely concordant with immune pressure. All
of these changes were accompanied by amino acid substitutions that reduced the binding of
different monoclonal antibodies (Fig. S6B).
Based on these findings, we propose a new hypothesis for antigenic drift (Fig. S7). Immune
individuals select single point mutants with increased receptor binding avidity and under
optimal circumstances (for the virus), diminished antigenicity. Transmission to a non-immune
individual leads to selection of mutants with decreased receptor binding. Since binding avidity
alteringsubstitutions exist throughout the globular domain, they frequently modify
antigenicity, even when this is not a selecting factor. Repeating the cycle, results in constant
modulation of binding avidity along with steady alterations in antigenicity, even in the absence
of antibody selection. Our model posits that cellular receptor binding alone exerts selection
pressure for a substantial fraction of substitutions in defined antigenic regions, explaining the
fixation of 30% of mutations in the globular domain outside defined antigenic regions (16).
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The properties of recent human isolates are consistent with this model. A/Panama/2007/99, the
2003–2004 vaccine strain, did not match the circulating A/Fujian/411/02 strain by HAI assays.
This difference was attributed to two amino acid substitutions (17). Remarkably, one
substitution is at residue 156, which we identify as playing a critical dual role in Sb antigenicity/
receptor binding avidity, while the other is at residue 155, which is immediately adjacent to
the sialic acid binding site, and also located in the Sb site. During the antigenic evolution of
H3N2 viruses from 1968 to 2003, a limited number of amino acids (in one case, a single N to
K substitution increasing positive charge) dictate HAI escape from polyclonal sera (18).
This model complements recent work emphasizing the importance of HA receptor specificity
in influenza virus species and organ tropism (19). Receptor specificity and affinity are
intimately related physiochemically, as demonstrated by our observation that each of the first
generation absorptive mutants (E156K, E158K, E246G) exhibits a unique avidity profile
against the panel of sialylated oligosaccharides (Fig. S3). Since host selection for optimal HA
receptor binding avidity generates mutants with altered receptor binding specificity, this is a
confounding factor in interpreting the evolutionary selection forces that generate IAV isolates
with altered glycan specificities.
In our model, antigenic drift is accelerated by sequential passage of influenza A virus between
immune and non-immune individuals (Fig. S7), which in the human population, are nearly all
children. Therefore, decreasing the naïve population size by increasing pediatric influenza A
virus vaccination rates will likely retard antigenic drift and temporally extend the effectiveness
of influenza vaccines. Monitoring binding avidity of circulating viral isolates may facilitate
the accurate prediction of mutants with epidemic potential.
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Fig. 1. In vivo influenza virus passaging selects for mutants with altered binding avidity
(A) HA and NA genes were sequenced in lung homogenates from 3 independent PR8 stocks
serially passaged in vaccinated and naïve Swiss mice. (B) Location of in vivo selected HA
amino acid substitutions in mutant viruses. (C) PR8 and mutant viruses were tested for escape
from anti-PR8 polyclonal antibodies by HAI using turkey erythrocytes or (D) virus
neutralization assays using MDCK cells. Data are expressed as inverse dilutions of serum and
are representative of three (HAI) or two (virus neutralization) experiments. Means +/− SEM
are shown in panel D. (E) Polyclonal antibody binding to HA was assessed by flow cytometry
after adding different dilutions of polyclonal antibody to L929 cells infected with the indicated
virus followed by the addition of anti-mouse FITC. Shown is mean florescence intensity (MFI)
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after normalizing HA expression based on the binding of a mixture of Ca monoclonal
antibodies or a NA specific monoclonal antibody (for the H3 HA/PR8 NA virus). Polyclonal
antibodies bind nearly exclusively to HA, as inferred from their low binding to the H3 HA/
PR8 NA infected cells. Data are representative of three independent experiments. (F) Cellular
receptor binding avidities were determined by hemagglutination of turkey erythrocytes pre-
treated with RDE. Data are expressed as the maximal amount of RDE that allowed full
agglutination. Data are representative of three independent experiments.
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Fig. 2. Numerous HA amino acid substitutions simultaneously modulate receptor binding and
escape from polyclonal antibodies
(A) Cellular avidities of 40 viruses with single HA amino acid substitutions were determined
using RDE-treated turkey erythrocytes. The percentages of viruses within each antigenic group
with altered binding are shown. (B) Individual mutants were tested for their abilities to escape
PR8 polyclonal antibodies by HAI. Data are plotted as ability to escape polyclonal antibodies
vs cellular receptor binding avidity. Means are represented as dots and the 95% confidence
interval is represented by dashed lines. (C) Locations of HA amino acid substitutions that
promote increased avidity are shown in yellow. (D) Net charge change of mutant viruses was
determined. n = number of viruses in each group. Means +/− SEM are shown.
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Fig. 3. Removal of polyclonal antibody selection promotes decreased receptor binding of in vivo
selected mutants
(A) Mutant viruses were tested for agglutination of RDE-treated turkey erythrocytes.
REV=virus with amino acid reversion of original mutation. (B) Mutant viruses were tested for
escape from PR8 polyclonal antibodies by HAI. Receptor binding avidities (C) and ability to
escape PR8 polyclonal antibodies (D) were also determined for the virus that was isolated after
further passage in heavily vaccinated mice.
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